HOME >> BIOLOGY >> NEWS
Two-pronged attack targeting EGF receptor hinders cancer cell growth

Hitting the epidermal growth factor receptor (EGFR) both high and low with a combination of drugs for targeted cancer therapy curbs cancer cell growth more effectively than using the drugs each by themselves, researchers from the University of Wisconsin-Madison reported in the August 1 issue of the journal Cancer Research.

EGFR drives unregulated growth in many types of cancer, and the new molecular cancer drugs, cetuximab (Erbitux, ImClone), and gefitinib (Iressa, AstraZeneca) have recently gained FDA approval as therapeutics targeted at the EGFR to inhibit cancer cell proliferation. A third EGFR inhibiting drug, and erlotinib (Tarceva, Genentech), may have FDA approval within a year.

The Wisconsin study examined the combined effect of Erbitux with either Iressa or Tarceva to control growth of head and neck, prostate, and lung cancer cell lines grown in culture, and lung cancer tumors developing in animals.

Tandem application of either Erbitux and Iressa, or Erbitux and Tarceva, proved synergistically more effective than single drug treaent at several levels.

"The combination of Erbitux with either Iressa or Tarceva inhibited cancer cell growth both in cell culture and in live animals more effectively than any of the drugs alone," said the study's senior author, Paul Harari, M.D., associate professor of human oncology, University of Wisconsin Medical School and Comprehensive Cancer Center.

"The impact of these drugs in combination exceeded the effect each had on controlling the growth, cellular signaling, and tumor development when administered alone," added Shyhmin Huang, Ph.D., a senior scientist in Harari's laboratory and lead author on the publication.

The anti-EGFR drugs are of two types:

  • The monoclonal antibody Erbitux hits the EGFR high, binding to a specific site on the receptor outside the cell membrane. Erbitux blocks the receptor from responding to extracellular signals that tu
    '"/>


Contact: Russell Vanderboom, PhD
vanderboom@aacr.org
215-440-9300
American Association for Cancer Research
1-Aug-2004


Page: 1 2 3

Related biology news :

1. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
2. Smart gene therapy protects against damage from heart attack
3. Reading hexametric rhyme supports cardiac synchronization, especially after a heart attack
4. New standard to help diagnose heart attacks
5. Variation of gene associated with decreased risk of heart attack and stroke
6. Dampened hopes for transplanting bone marrow stem cells in heart attacks
7. Protein may help prevent autoimmune attacks
8. Biosensor-regulated gene therapy reduces heart attack damage in mice
9. Lion attacks on livestock in Africa are significant but manageable
10. New approach limits damage after heart attack and improves survival, say Scripps Research scientists
11. Stem-cell therapy could have benefits and risks for heart-attack PTs

Post Your Comments:
(Date:10/29/2014)... lose their hair as a consequence of chemotherapy will ... the scalp cooling technology that prevents hair loss. , ... pioneered by global scalp cooling manufacturing company, Paxman Coolers, ... department of the University of Huddersfield. , The research ... has a background in the pharmacology of cancer treatment, ...
(Date:10/29/2014)... registration is open for the Society ... Meeting. SIR 2015 is the one place ... and related health care professionals can come ... science and technologies being presented, discussed and ... in minimally invasive, image-guided medicine, SIR 2015 ...
(Date:10/29/2014)... of chemicals from household and industrial products are in ... But for most of them, scientists have yet to ... the first step toward doing that by estimating which ... method is published in the ACS journal Environmental ... colleagues note that the risks to human health of ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2
(Date:10/31/2014)... 31, 2014 Having access to safe ... uphill battle in many corners of the globe. It’s ... community in northwestern Bolivia where many have been sickened ... from Fairfield University’s School of Engineering has been working ... Campesina (UAC), “the united college for the peasants.” A ...
(Date:10/31/2014)... Burlington, MA (PRWEB) October 31, 2014 ... is hosting a free learning webinar to introduce its ... managers, standards directors and biostatisticians. , Launched in September, ... the company's suite of clinical trial automation tools. For ... in a web browser. And by introducing Formations – ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Stronger ... healthcare, construction, finance and consumer electronics will help ... reason, industry research firm IBISWorld has added a ... its growing industry report collection. , The Biometrics ... for biometric technologies such as fingerprint, iris, retina ...
(Date:10/30/2014)... 30, 2014  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that ... on Thursday, November 6, 2014. Following the announcement, ... conference call and webcast at 4:30pm ET to ... business update. The live webcast can ...
Breaking Biology Technology:Fairfield University School of Engineering project reduces illness in rural community 2Fairfield University School of Engineering project reduces illness in rural community 3Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 3Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2
Cached News: